SO YOU DRIVE to the local park for your morning walk, drive and take a Metro to your office, where you grab the lift to the third floor, and then you repeat the commute in the evening. If you have to queue up for an autorickshaw, you crib about last-mile connectivity to your doorstep, instead of walking that mile.
That’s rising urbanisation and sedentary lifestyles for you. The bane of modern India. But they are a boon for pharmaceutical companies such as Eli Lilly & Co, whose 146-year history has been powered by a list of firsts: the first treatment for pernicious anaemia, the first mass-produced antibiotic, the mass-produced Salk polio vaccine, human insulin, and pills for clinical depression and schizophrenia, among others.
Lilly is now betting that its drugs for obesity and diabetes will power its revenues into a higher trajectory. Especially as obesity and diabetes are like the proverbial chicken and egg situation: which came first? Lilly’s portfolio also has your heart covered (obesity and diabetes can get your heart).
RESPONDING TO THE DUAL CRISIS
US-based Lilly is no stranger to India. In 1993, it set up a unit to bring its treatments for diabetes, a range of cancers, osteoporosis, rheumatoid arthritis, men’s health, and growth hormone deficiency.
Now, it aims to bring to India its hugely successful drug Mounjaro that is used to treat Type 2 diabetes and as an anti-obesity drug for adults. In the US, Lilly has launched two different brands: Zepbound for obesity; and Mounjaro for Type 2 diabetes. In both, the active ingredient is tirzepatide. Mounjaro’s revenue exceeded $5 billion in 2023, its first full year on the market.
According to the FDA, approximately 70% of American adults are obese or overweight, and many of those overweight have a weight-related condition.
هذه القصة مأخوذة من طبعة March 31, 2024 من Business Today India.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة March 31, 2024 من Business Today India.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
"Moving to cloud helped us grow❞
What was the problem you were grappling with?
She's Got Time
MORE WOMEN ARE BECOMING WATCH CONNOISSEURS, SEEKING OUT BOTH JEWELLED AND TECHNICAL WATCHES FOR THEIR STYLE AND CRAFTSMANSHIP
RISING STAR
PARUL GULATI IS a name that's been steadily gaining prominence in the Indian entertainment industry after she appeared on season 2 of Shark Tank in 2023. She has become a multifaceted personality who effortlessly transitions between acting and entrepreneurship.
Building on a Legacy
WHEN ZAHABIYA KHORAKIWALA stepped into her role as Managing Director of Wockhardt Hospitals over a decade ago, she confronted formidable challenges that have since turned into achievements.
LEADER IN INNOVATION
AS FEDEX'S PRESIDENT (Middle East, Indian subcontinent and Africa), Kami Viswanathan has a lot on her plate.
WAITING IN THE WINGS
Here are those who missed out as they have not yet completed a year in office; they'll be strong contenders in 2025
A DECENT PROPOSAL
IN TODAY'S WORLD OF TRYING TO CREATE AN EQUITABLE SPACE, BOTH MEN AND WOMEN CONTRIBUTE TO THEIR HOUSEHOLDS. WOMEN ARE ENCOURAGED TO HAVE THEIR OWN SAVINGS POOL AND INVESTMENT ROUTINE. GIVEN THIS, HOW SHOULD FUTURE BRIDES APPROACH FINANCIAL PLANNING?
Women and the STEM Bias
EMPOWERING WOMEN IN STEM WILL NOT ONLY BENEFIT INDIVIDUALS, BUT ALSO STRENGTHEN THE ENTIRE INDUSTRY, DRIVING INNOVATION AND PROGRESS.
ROCKET WOMEN
WOMEN IN INDIA ARE NOT ONLY VENTURING INTO SPACE BUT ARE ALSO STARTING TO SPEARHEAD THE COUNTRY'S EFFORTS IN THE GLOBAL SPACE RACE.
ONE STEP FORWARD
THE NUMBER OF WOMEN INDEPENDENT DIRECTORS IS GROWING STEADILY, BUT IT'S A LONG WAY FROM GENDER PARITY. MUCH MORE NEEDS TO BE DONE TO BREAK THE GLASS CEILING IN BOARDROOMS.
